|Systematic (IUPAC) name|
|Metabolism||Hepatic, including CYP3A4 and other pathways|
|Half life||12-15 hrs|
|Excretion||Urine (as metabolites)|
|Legal status||Schedule IV (US) ℞ Prescription only|
Armodafinil (Nuvigil) is a stimulant-like drug produced by the pharmaceutical company Cephalon Inc., which was approved by the FDA on June 15, 2007.  Armodafinil is the active (−)-(R)-enantiomer of the racemic drug modafinil (Provigil).
Cephalon plans to conduct clinical trials evaluating the use of Nuvigil as a treatment for serious medical conditions such as bipolar depression, cognition abnormalities associated with schizophrenia, and excessive sleepiness, and fatigue in conditions such as Parkinson's disease, cancer,[2 ] and narcolepsy, which is a sleep disorder. Nuvigil is protected by a U.S. patent expiring in 2023 that claims the Form 1 polymorph of armodafinil.
Nuvigil is available for prescription as of June 1, 2009. As of January 6th, 2010, it is being considered for the first FDA-approved medicinally-specific drug for combating jet-lag